Publicaciones en colaboración con investigadores/as de GlaxoSmithKline (United Kingdom) (92)

2023

  1. A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR)

    The European respiratory journal, Vol. 61, Núm. 2

  2. Academia and industry agreement on a feasibility tool for first-time-in-human clinical trial units

    Clinical and Translational Science, Vol. 16, Núm. 12, pp. 2421-2428

  3. Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA)

    eClinicalMedicine, Vol. 57

  4. Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12-23 Months of Age

    The Journal of infectious diseases, Vol. 227, Núm. 11, pp. 1293-1302

  5. Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study

    eClinicalMedicine, Vol. 62

  6. Societal Preferences for Meningococcal B Vaccination in Children: A Discrete Choice Experiment in Spain

    Infectious Diseases and Therapy, Vol. 12, Núm. 1, pp. 157-175

  7. Sperm protein antigen 17 and Sperm flagellar 1 cancer testis antigens are expressed in a rare case of ciliated foregut cyst of the common hepatic duct

    Pathology Research and Practice, Vol. 247

2022

  1. An open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension

    Pulmonary Circulation, Vol. 12, Núm. 1

  2. Non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial

    The Lancet. Respiratory medicine, Vol. 10, Núm. 5, pp. 435-446

2021

  1. Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies

    HIV Research and Clinical Practice, Vol. 23, Núm. 1, pp. 9-14

2020

  1. ADVANCE system testing: Benefit-risk analysis of a marketed vaccine using multi-criteria decision analysis and individual-level state transition modelling

    Vaccine, Vol. 38, pp. B65-B75

  2. ADVANCE system testing: Can coverage of pertussis vaccination be estimated in European countries using electronic healthcare databases: An example

    Vaccine, Vol. 38, pp. B22-B30

  3. ADVANCE system testing: Can safety studies be conducted using electronic healthcare data? An example using pertussis vaccination

    Vaccine, Vol. 38, pp. B38-B46

  4. ADVANCE system testing: Estimating the incidence of adverse events following pertussis vaccination in healthcare databases with incomplete exposure data

    Vaccine, Vol. 38, pp. B47-B55

  5. Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials

    Journal of acquired immune deficiency syndromes (1999), Vol. 85, Núm. 3, pp. 325-330

  6. Characteristics and treatment regimens across ERS SHARP severe asthma registries

    European Respiratory Journal, Vol. 55, Núm. 1

  7. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: A phase 3, randomized clinical trial

    Clinical Infectious Diseases, Vol. 70, Núm. 2, pp. 181-190

  8. Impact of tetanus-diphtheria-acellular pertussis immunization during pregnancy on subsequent infant immunization seroresponses: follow-up from a large randomized placebo-controlled trial

    Vaccine, Vol. 38, Núm. 8, pp. 2105-2114

  9. Quadrivalent Influenza Vaccine Prevents Illness and Reduces Healthcare Utilization Across Diverse Geographic Regions During Five Influenza Seasons: A Randomized Clinical Trial

    The Pediatric infectious disease journal, Vol. 39, Núm. 1, pp. e1-e10

2019

  1. Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)

    Pulmonary Circulation, Vol. 9, Núm. 2